PLX R18

Drug Profile

PLX R18

Alternative Names: PLX R 18; PLX RAD

Latest Information Update: 01 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hadassah Medical School; Pluristem Therapeutics
  • Developer Case Western Reserve University; Fukushima Medical University; Hadassah Medical School; National Institute of Allergy and Infectious Diseases; Pluristem Therapeutics
  • Class Stem cell therapies
  • Mechanism of Action Bone marrow cell stimulants; Cell differentiation modulators; Cell replacements; Stem cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute radiation syndrome; Aplastic anaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase I Aplastic anaemia; Graft-versus-host disease
  • Preclinical Acute radiation syndrome

Most Recent Events

  • 23 Oct 2017 Pluristem Therapeutics has patent protection for PLX R18 in European Union
  • 19 Oct 2017 Preclinical trials in Acute radiation syndrome in Japan (IM)
  • 19 Oct 2017 PLX R18 receives Orphan Drug status for Acute radiation syndrome in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top